Open Access

MicroRNA‑769‑3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β‑catenin signaling pathway

  • Authors:
    • Kai Wang
    • Shasha Yang
    • Yishen Gao
    • Caihong Zhang
    • Qiangbo Sui
  • View Affiliations

  • Published online on: November 21, 2019     https://doi.org/10.3892/ol.2019.11135
  • Pages: 992-1000
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Accumulating evidence suggests the crucial role of microRNAs (miRNAs) in human cancers. The present study aimed to investigate the clinical and functional roles of miR‑769‑3p in glioma, as well as the underlying molecular mechanisms. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to determine the expression levels of miR‑769‑3p in glioma tissues and cells. Receiver operating characteristic (ROC) curve analysis was applied to calculate the diagnostic value of miR‑769‑3p. The 5‑year survival rate of patients was calculated using Kaplan‑Meier analysis and Cox regression analysis. Cell experiments were used to investigate the functional role of miR‑769‑3p in glioma. The gene target of miR‑769‑3p was predicted by TargetScan. Changes in the levels of Wnt signaling‑related proteins were measured by western blotting. miR‑769‑3p was significantly downregulated in glioma tissues and serum, as well as in glioma cell lines (P<0.001). miR‑769‑3p expression was significantly associated with the World Health Organization grade and Karnofsky performance score. The ROC curves demonstrated that serum miR‑769‑3p level reliably distinguished patients with glioma from healthy individuals. High tissue miR‑769‑3p expression predicted poor overall survival in patients with glioma (log‑rank P=0.001) and was identified as an independent prognostic factor. In addition, zinc finger E‑box binding homeobox 2 (ZEB2) was demonstrated to be a direct target of miR‑769‑3p in glioma cells using a luciferase assay. miR‑769‑3p upregulation suppressed the activity of the Wnt/β‑catenin signaling pathway in glioma cells. In conclusion, miR‑769‑3p may serve as a diagnostic and prognostic biomarker in patients with glioma and target ZEB2 to inhibit tumor progression via the Wnt/β‑catenin signaling pathway. miR‑769‑3p may be a novel therapeutic target for the treatment of glioma.
View Figures
View References

Related Articles

Journal Cover

January 2020
Volume 19 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Wang, K., Yang, S., Gao, Y., Zhang, C., & Sui, Q. (2020). MicroRNA‑769‑3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β‑catenin signaling pathway. Oncology Letters, 19, 992-1000. https://doi.org/10.3892/ol.2019.11135
MLA
Wang, K., Yang, S., Gao, Y., Zhang, C., Sui, Q."MicroRNA‑769‑3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β‑catenin signaling pathway". Oncology Letters 19.1 (2020): 992-1000.
Chicago
Wang, K., Yang, S., Gao, Y., Zhang, C., Sui, Q."MicroRNA‑769‑3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β‑catenin signaling pathway". Oncology Letters 19, no. 1 (2020): 992-1000. https://doi.org/10.3892/ol.2019.11135